Overview

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788 compared with placebo, and to investigate the safety and efficacy of long term dosing of R788 in patients with chronic idiopathic thrombocytopenic purpura.
Phase:
Phase 3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.